Oral Chemotherapy and Compliance

A multidisciplinary approach, improved communication with the patient, and counseling patients about the risks of medication nonadherence are essential to overcome the barriers to adherence and maximize the benefits of oral anticancer therapy. A better understanding of the unique challenges associated with the use of oral anticancer therapies and the importance of adherence to therapy enables oncologists, nurses, and pharmacists to effectively communicate the key clinical aspects to their patients throughout the disease course. In collaboration with the medical oncologists and other multidisciplinary team members, nurses and pharmacists should participate in efforts to optimize the oral anticancer therapy protocol of the individual patient with the appropriate management of medication-related side effects and reducing the complexity of regimen. Educating health care professionals about the interventions to improve adherence will enable the integration of these strategies into routine clinical practice to improve adherence to oral anticancer therapy among their patients.

Target Audience

This educational program is designed to meet the educational needs of oncology nurses who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Describe the challenges associated with the use of oral anticancer therapies
  • Discuss the interventions that have been evaluated to assess and improve adherence to oral anticancer therapies
  • Identify the resources and requirements needed for the implementation of an effective strategy to improve adherence to oral anticancer therapy
Additional information
Supporters: 

This activity is supported by educational grants from:

  • AstraZeneca
  • Genentech, a member of the Roche Group
  • Novartis
  • Pfizer Inc.
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Taiho Oncology, Inc.

This activity is supported by independent medical education grants from:

  • Bristol-Myers Squibb
  • Celgene Corporation

This activity is supported by independent educational grants from:

  • AbbVie
  • Incyte
  • Merck & Co., Inc.
Course summary
Available credit: 
  • 0.75 ANCC contact hours
  • 0.75 Participation
Course opens: 
07/10/2020
Course expires: 
03/01/2021
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 2020 Nursing Program: Advancing Oncology Nursing™

Caroline Faylor, PharmD
Fred & Pamela Buffett Cancer Center

Susan Franco, RN, BSN, OCN
Fred & Pamela Buffett Cancer Center

 

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions  
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers  
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures
The faculty listed below discloses no relevant financial relationships:
Carolyn Faylor, PharmD
Susan Franco, RN, BSN, OCN

NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein

The NCCN Clinical staff listed below discloses no relevant financial relationships:
Hema Sundar, PhD

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses
NCCN designates this educational activity for a maximum of 0.75 contact hour.

Available Credit

  • 0.75 ANCC contact hours
  • 0.75 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: